Evidence map›Paper›PMID 41908819›Full record

ArticleFrontiers in pharmacology2026

Exploratory pharmacokinetic-pharmacodynamic characterization and safety of standardized

Phanit Songvut, Paruspak Payoong, Pilailuk Akkapaiboon Okada, Noppawan Rittapai, Sumitra Suntararuks, Jaratluck Akanimanee, Nuchanart Rangkadilok, Duangchit Panomvana, Porranee Puranajoti, Jutamaad Satayavivad

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Phanit SongvutLaboratory of Pharmacology, Chulabhorn Research Institute, Bangkok, Thailand.
Paruspak PayoongDepartment of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand.
Pilailuk Akkapaiboon OkadaNational Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand.
Noppawan RittapaiLaboratory of Pharmacology, Chulabhorn Research Institute, Bangkok, Thailand.
Sumitra SuntararuksLaboratory of Pharmacology, Chulabhorn Research Institute, Bangkok, Thailand.
Jaratluck AkanimaneeLaboratory of Pharmacology, Chulabhorn Research Institute, Bangkok, Thailand.
Nuchanart RangkadilokLaboratory of Pharmacology, Chulabhorn Research Institute, Bangkok, Thailand.
Duangchit PanomvanaTranslational Research Unit, Chulabhorn Research Institute, Bangkok, Thailand.
Porranee PuranajotiTranslational Research Unit, Chulabhorn Research Institute, Bangkok, Thailand.
Jutamaad SatayavivadLaboratory of Pharmacology, Chulabhorn Research Institute, Bangkok, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: A single-center PK/PD clinical trial with two sequential phases (single-dose followed by multiple-dose) was conducted. Patients with mild COVID-19 received standardized Results: Rapid absorption and elimination with limited systemic exposure supported repeated dosing to maintain exposure over the 5-day period. PK/PD analysis demonstrated a sigmoidal, saturable exposure-response relationship. The mean area under the concentration-time curve (AUC Conclusion: These findings provide preliminary evidence regarding the pharmacokinetics, dose-exposure characteristics, and short-term tolerability of standardized

Indexed as

Andrographis paniculataCOVID-19pharmacodynamicspharmacokineticssafety

Identifiers

PMID41908819
PMCPMC13022710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.